MTPConnect announced that Dr Alexander Staudacher, researcher at the Centre of Cancer Biology was awarded the REDI (Researcher Exchange and Development within Industry) Fellowship.
The program provides financial support to Australian, international and/or multinational medical technology or pharmaceutical (MTP) companies to bring the best talent in-house for up to twelve-months to work on priority medical research projects.
Dr Alexander Staudacher is a postdoctoral research scientist working in CCB’s Translational Oncology Laboratory. Dr Staudacher will be working closely with Melbourne-headquartered Telix Pharmaceuticals to create a development roadmap for the commercialisation of humanised APOMAB™ for clinical combination therapy - a promising antibody technology for treatment of cancer. This roadmap will be essential to plan the manufacturing activities, nonclinical and clinical studies required to take this novel technology beyond the research phase and into clinical use with the aim to improve cancer patients’ lives. Telix Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR).
